
Elicio Therapeutics Inc
NASDAQ:ELTX

Fundamental Analysis


Revenue & Expenses Breakdown
Elicio Therapeutics Inc
Balance Sheet Decomposition
Elicio Therapeutics Inc
Current Assets | 22.6m |
Cash & Short-Term Investments | 22.1m |
Other Current Assets | 510k |
Non-Current Assets | 6.9m |
PP&E | 5.6m |
Other Non-Current Assets | 1.3m |
Free Cash Flow Analysis
Elicio Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Elicio Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-44.6m
USD
|
Operating Income
|
-44.6m
USD
|
Other Expenses
|
-10m
USD
|
Net Income
|
-54.6m
USD
|
ELTX Profitability Score
Profitability Due Diligence
Elicio Therapeutics Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

Score
Elicio Therapeutics Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
ELTX Solvency Score
Solvency Due Diligence
Elicio Therapeutics Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Score
Elicio Therapeutics Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ELTX Price Targets Summary
Elicio Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
ELTX
is 12.75 USD
with a low forecast of 12.12 USD and a high forecast of 13.65 USD.
Dividends
Current shareholder yield for ELTX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?